A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania

Mauricio Tohen, Joseph F. Goldberg, Ana Maria Gonzalez-Pinto Arrillaga, Jean M. Azorin, Eduard Vieta, Marie Christine Hardy-Bayle, William B. Lawson, Robin A. Emsley, Fan Zhang, Robert W. Baker, Richard C. Risser, Madhav A. Namjoshi, Angela R. Evans, Alan Breier

Research output: Contribution to journalArticle

212 Citations (Scopus)

Abstract

Background: This randomized controlled trial compares the efficacy and safety of olanzapine vs haloperidol, as well as the quality of life of patients taking these drugs, in patients with bipolar mania. Methods: The design consisted of 2 successive, 6-week, double-blind periods and compared flexible dosing of olanzapine (5-20 mg/d, n = 234) with haloperidol (3-15 mg/d, n=219). Results: Rates of remission (Young-Mania Rating Scale score of ≤12 and 21-item Hamilton Rating Scale for Depression score of ≤8 at week 6) were similar for olanzapine- and haloperidol-treated patients (52.1% vs 46.1%, respectively; P=.15). For the subgroup of patients whose index episode did not include psychotic features, rates of remission were significantly greater for the olanzapine group compared with the haloperidol group (56.7% vs 41.6%, P=.04). Relapse into an affective episode (mania and/or depression) occurred in 13.1% and 14.8% of olanzapine- and haloperidol-treated patients, respectively (P=.56). Switch to depression occurred significantly more rapidly with haloperidol than with olanzapine when using survival analysis techniques (P=.04), and significantly more haloperidol-treated patients experienced worsening of extrapyramidal symptoms, as indicated by several measures. Weight gain was significantly greater in the olanzapine group compared with the haloperidol group (2.82 vs 0.02 kg, P

Original languageEnglish (US)
Pages (from-to)1218-1226
Number of pages9
JournalArchives of General Psychiatry
Volume60
Issue number12
DOIs
StatePublished - Dec 2003

Fingerprint

olanzapine
Haloperidol
Bipolar Disorder
Therapeutics
Depression
Survival Analysis
Weight Gain

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Tohen, M., Goldberg, J. F., Gonzalez-Pinto Arrillaga, A. M., Azorin, J. M., Vieta, E., Hardy-Bayle, M. C., ... Breier, A. (2003). A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. Archives of General Psychiatry, 60(12), 1218-1226. https://doi.org/10.1001/archpsyc.60.12.1218

A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. / Tohen, Mauricio; Goldberg, Joseph F.; Gonzalez-Pinto Arrillaga, Ana Maria; Azorin, Jean M.; Vieta, Eduard; Hardy-Bayle, Marie Christine; Lawson, William B.; Emsley, Robin A.; Zhang, Fan; Baker, Robert W.; Risser, Richard C.; Namjoshi, Madhav A.; Evans, Angela R.; Breier, Alan.

In: Archives of General Psychiatry, Vol. 60, No. 12, 12.2003, p. 1218-1226.

Research output: Contribution to journalArticle

Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, Azorin, JM, Vieta, E, Hardy-Bayle, MC, Lawson, WB, Emsley, RA, Zhang, F, Baker, RW, Risser, RC, Namjoshi, MA, Evans, AR & Breier, A 2003, 'A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania', Archives of General Psychiatry, vol. 60, no. 12, pp. 1218-1226. https://doi.org/10.1001/archpsyc.60.12.1218
Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC et al. A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. Archives of General Psychiatry. 2003 Dec;60(12):1218-1226. https://doi.org/10.1001/archpsyc.60.12.1218
Tohen, Mauricio ; Goldberg, Joseph F. ; Gonzalez-Pinto Arrillaga, Ana Maria ; Azorin, Jean M. ; Vieta, Eduard ; Hardy-Bayle, Marie Christine ; Lawson, William B. ; Emsley, Robin A. ; Zhang, Fan ; Baker, Robert W. ; Risser, Richard C. ; Namjoshi, Madhav A. ; Evans, Angela R. ; Breier, Alan. / A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania. In: Archives of General Psychiatry. 2003 ; Vol. 60, No. 12. pp. 1218-1226.
@article{e878f58c9feb45478eb5ae0be286c3e0,
title = "A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania",
abstract = "Background: This randomized controlled trial compares the efficacy and safety of olanzapine vs haloperidol, as well as the quality of life of patients taking these drugs, in patients with bipolar mania. Methods: The design consisted of 2 successive, 6-week, double-blind periods and compared flexible dosing of olanzapine (5-20 mg/d, n = 234) with haloperidol (3-15 mg/d, n=219). Results: Rates of remission (Young-Mania Rating Scale score of ≤12 and 21-item Hamilton Rating Scale for Depression score of ≤8 at week 6) were similar for olanzapine- and haloperidol-treated patients (52.1{\%} vs 46.1{\%}, respectively; P=.15). For the subgroup of patients whose index episode did not include psychotic features, rates of remission were significantly greater for the olanzapine group compared with the haloperidol group (56.7{\%} vs 41.6{\%}, P=.04). Relapse into an affective episode (mania and/or depression) occurred in 13.1{\%} and 14.8{\%} of olanzapine- and haloperidol-treated patients, respectively (P=.56). Switch to depression occurred significantly more rapidly with haloperidol than with olanzapine when using survival analysis techniques (P=.04), and significantly more haloperidol-treated patients experienced worsening of extrapyramidal symptoms, as indicated by several measures. Weight gain was significantly greater in the olanzapine group compared with the haloperidol group (2.82 vs 0.02 kg, P",
author = "Mauricio Tohen and Goldberg, {Joseph F.} and {Gonzalez-Pinto Arrillaga}, {Ana Maria} and Azorin, {Jean M.} and Eduard Vieta and Hardy-Bayle, {Marie Christine} and Lawson, {William B.} and Emsley, {Robin A.} and Fan Zhang and Baker, {Robert W.} and Risser, {Richard C.} and Namjoshi, {Madhav A.} and Evans, {Angela R.} and Alan Breier",
year = "2003",
month = "12",
doi = "10.1001/archpsyc.60.12.1218",
language = "English (US)",
volume = "60",
pages = "1218--1226",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania

AU - Tohen, Mauricio

AU - Goldberg, Joseph F.

AU - Gonzalez-Pinto Arrillaga, Ana Maria

AU - Azorin, Jean M.

AU - Vieta, Eduard

AU - Hardy-Bayle, Marie Christine

AU - Lawson, William B.

AU - Emsley, Robin A.

AU - Zhang, Fan

AU - Baker, Robert W.

AU - Risser, Richard C.

AU - Namjoshi, Madhav A.

AU - Evans, Angela R.

AU - Breier, Alan

PY - 2003/12

Y1 - 2003/12

N2 - Background: This randomized controlled trial compares the efficacy and safety of olanzapine vs haloperidol, as well as the quality of life of patients taking these drugs, in patients with bipolar mania. Methods: The design consisted of 2 successive, 6-week, double-blind periods and compared flexible dosing of olanzapine (5-20 mg/d, n = 234) with haloperidol (3-15 mg/d, n=219). Results: Rates of remission (Young-Mania Rating Scale score of ≤12 and 21-item Hamilton Rating Scale for Depression score of ≤8 at week 6) were similar for olanzapine- and haloperidol-treated patients (52.1% vs 46.1%, respectively; P=.15). For the subgroup of patients whose index episode did not include psychotic features, rates of remission were significantly greater for the olanzapine group compared with the haloperidol group (56.7% vs 41.6%, P=.04). Relapse into an affective episode (mania and/or depression) occurred in 13.1% and 14.8% of olanzapine- and haloperidol-treated patients, respectively (P=.56). Switch to depression occurred significantly more rapidly with haloperidol than with olanzapine when using survival analysis techniques (P=.04), and significantly more haloperidol-treated patients experienced worsening of extrapyramidal symptoms, as indicated by several measures. Weight gain was significantly greater in the olanzapine group compared with the haloperidol group (2.82 vs 0.02 kg, P

AB - Background: This randomized controlled trial compares the efficacy and safety of olanzapine vs haloperidol, as well as the quality of life of patients taking these drugs, in patients with bipolar mania. Methods: The design consisted of 2 successive, 6-week, double-blind periods and compared flexible dosing of olanzapine (5-20 mg/d, n = 234) with haloperidol (3-15 mg/d, n=219). Results: Rates of remission (Young-Mania Rating Scale score of ≤12 and 21-item Hamilton Rating Scale for Depression score of ≤8 at week 6) were similar for olanzapine- and haloperidol-treated patients (52.1% vs 46.1%, respectively; P=.15). For the subgroup of patients whose index episode did not include psychotic features, rates of remission were significantly greater for the olanzapine group compared with the haloperidol group (56.7% vs 41.6%, P=.04). Relapse into an affective episode (mania and/or depression) occurred in 13.1% and 14.8% of olanzapine- and haloperidol-treated patients, respectively (P=.56). Switch to depression occurred significantly more rapidly with haloperidol than with olanzapine when using survival analysis techniques (P=.04), and significantly more haloperidol-treated patients experienced worsening of extrapyramidal symptoms, as indicated by several measures. Weight gain was significantly greater in the olanzapine group compared with the haloperidol group (2.82 vs 0.02 kg, P

UR - http://www.scopus.com/inward/record.url?scp=10744221700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744221700&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.60.12.1218

DO - 10.1001/archpsyc.60.12.1218

M3 - Article

C2 - 14662554

AN - SCOPUS:10744221700

VL - 60

SP - 1218

EP - 1226

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 12

ER -